The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new findings from the Phase 3 SPARTAN clinical trial that showed treatment with ERLEADA™, an investigational, next-generation androgen receptor inhibitor, decreased risk of metastasis or death by 72 percent and improved median metastasis-free survival (MFS) by more than two years (difference of 24.3 months) in patients…